Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codexis (CDXS) agreed with an unnamed siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis platform. Codexis will make oligonucleotide fragments through a fully enzymatic process and supply them to the innovator, which will join them into a final duplex.
The collaboration will compare those fragments with ones made through conventional solid-phase synthesis, assessing purity, product quality and how well the fragments join. The results will help the innovator assess the technology for potential future clinical development programs. Codexis previously demonstrated full-length siRNA synthesis with control of phosphorothioate stereochemistry at TIDES USA 2026.
Positive
- Customer agreement advances evaluation of Codexis’s stereo-defined siRNA manufacturing approach.
- Fully enzymatic fragments will be produced by Codexis and supplied to the innovator.
- Full-length siRNA synthesis with controlled phosphorothioate stereochemistry was demonstrated at TIDES USA 2026.
Negative
- Clinical development use remains potential and depends on the innovator’s assessment of the results.
- Purity, product quality and ligation performance still need comparison with conventional solid-phase synthesis.
Details
Market move: CDXS +3.03% in the Sep 28 session. siRNA manufacturing partnership
On Sep 28, the day this news came out, CDXS closed 3.03% above the previous close.
Data tracked by StockTitan Argus for the Sep 28 session.
Key Terms
sirna medical
phosphorothioate stereochemistry technical
solid-phase oligonucleotide synthesis technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis.
Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining momentum as a next-generation manufacturing paradigm for oligonucleotides due to its potential to enhance scalability, efficiency, and product quality.
The collaboration will also compare enzymatically synthesized fragments with conventional solid-phase oligonucleotide synthesis (SPOS), evaluating purity, product quality, and ligation performance. The results will allow the innovator to assess the technology's potential for future clinical development programs.
Alison Moore, PhD., President and CEO at Codexis, said: “This agreement is an important next step in bringing our latest ECO Synthesis capabilities to a customer. Working with a pioneer in the siRNA field offers an exciting opportunity to demonstrate how ECO Synthesis can deliver stereochemical control, which may offer both superior product quality and therapeutic performance to an innovator’s pipeline over assets produced using traditional solid phase chemistry methods.”
Codexis continues to advance the ECO Synthesis Manufacturing Platform as part of its strategy to industrialize scalable manufacturing solutions for complex oligonucleotide therapeutics.
About Codexis, Inc.
Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the Company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
+1 (650) 421-8100
ir@codexis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will Codexis and the siRNA innovator do under their agreement?
Codexis will use its ECO Synthesis platform to make stereo-defined oligonucleotide fragments through a fully enzymatic process. It will supply the fragments to the innovator, which will join them into a final duplex.